Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20719394 | 0.86 | MEN1 (0.36) | CNR2GAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20719250 | 0.84 | TSHR (0.37) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL16617001 | 0.80 | ABCB11 (0.35) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL20719128 | 0.79 | ALDH1A1 (0.38) | CYP1A2ABCB11CYP3A4PMP22CNR2 | |
| SCHEMBL3508448 | 0.76 | CD274 (0.37) | GAAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL9538404 | 0.75 | MEN1 (0.41) | GAAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20719216 | 0.74 | TNF (0.37) | CYP1A2CYP3A4TSHRSTING1DGAT1 | |
| SCHEMBL20719376 | 0.74 | GAA (0.33) | CYP1A2ABCB11CYP3A4TSHRHTR2A | |
| SCHEMBL20719426 | 0.74 | MAPT (0.35) | DGAT1GAAMAPTALDH1A1TDP1 | |
| SCHEMBL20719424 | 0.74 | MAPT (0.35) | DGAT1GAAMAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3055300-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | Pfizer Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2015052610-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052610-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PTGER3, PTGES3, PTGER2 | CYP1A2 1597/4885ABCB11 3854/4885CYP3A4 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.